| Citation | Professor Paul Workman is distinguished for his studies in the development of targeted treatments for human cancer. He pioneered the concept of using the HSP 90 molecular chaperone as a target and, through the development of 17AAG saw the need for an improved molecule and developed the drug NVP-AUY922. He has brought Pl3 kinase inhibitors, PKB inhibitors and five other targeted agents into clinical trial pioneering successful academic drug discovery in the UK and introducing highly effective methodologies in key developmental decision making (the Pharmacological Audit Trail) that are transforming the success rate of cancer treatment development. |